Optimal timing of G-CSF administration for effective autologous stem cell collection

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 806-812

  Kim, J E ^a   Yoo, C ^a   Kim, S ^a   Lee, D H ^a   Kim, S W ^a   Lee, J S ^a   Suh, C ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

administration time; efficacy; G CSF; peripheral blood progenitor cell collection

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CD34 SELECTION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECOMBINANT PROTEINS; REGISTRIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 79958108126     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.194     Document Type: Article

References (27)

1. Pierre F, Daniele B, Florenece G, Francosis A, Anne S, Veronique LC et al. Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells. Transfusion 2003; 43: 878-884.
2. Millar BC, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D et al. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998; 22: 469-475.
3. Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003; 122: 360-375. (Pubitemid 36951620)
4. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316. (Pubitemid 28122743)
5. Ergene U, Cagirgan S, Pehlivan M, Yilmaz M, Tombuloglu M. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). Transfus Apher Sci 2007; 36: 23-29. (Pubitemid 46341972)
6. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998; 101: 582-585. (Pubitemid 28266956)
7. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW et al. Optimizing dose and scheduling of filgrastim (granulocyte colony- stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
8. Kim S, Kim HJ, Park JS, Lee J, Chi HS, Park CJ et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742-747. (Pubitemid 41447809)
9. Watts MJ, Addison I, Ings SJ, Long SG, Hartley S, Warrington S et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration. Bone Marrow Transplant 1998; 21: 365-368. (Pubitemid 28080472)
10. Sato S, Kigawa J, Irie T, Itamochi H, Kanamori Y, Kamazawa S et al. Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer. Am J Clin Oncol 2002; 25: 289-290. (Pubitemid 34602554)
11. Assouline S, Sylvester MP, Carriere P, Shustik C, Laneuville P. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients. Transfusion 2006; 46: 174-179. (Pubitemid 43381750)
12. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449-454. (Pubitemid 40403346)
13. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-290. (Pubitemid 34229032)
14. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos Met al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19: 4014-4022. (Pubitemid 32976687)
15. Suh C, Kim S, Kim SH, Kim EK, Lee JL, Park KU et al. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004; 44: 1762-1768. (Pubitemid 39644062)
16. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003; 29: 29-37. (Pubitemid 36870843)
17. Yamaguchi E, Yamato K, Miyata Y. Kinetics of peripheral blood stem cell collection in large-volume leukapheresis for pediatric patients undergoing chemotherapy and adult patients before chemotherapy. J Hematother Stem Cell Res 2000; 9: 565-572.
18. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003; 18: 27-35. (Pubitemid 38021788)
19. Park KU, Kim SH, Suh C, Kim S, Lee SJ, Park JS et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67: 42-47. (Pubitemid 32336703)
20. Stroncek DF, Matthews CL, Follmann D, Leitman SF. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002; 42: 597-602.
21. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander AR. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004; 44: 104-110. (Pubitemid 38177144)
22. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
23. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284. (Pubitemid 351833805)
24. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 2007; 47: 2207-2216. (Pubitemid 350151197)
25. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-724.
26. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820. (Pubitemid 36410987)
27. Hoglund M, Smedmyr B, Bengtsson M, Totterman TH, Cour-Chabernaud V, Yver A et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study. Eur J Haematol 1997; 59: 177-183. (Pubitemid 27392094)